1
|
Varaldo E, Prencipe N, Berton AM, Cuboni D, Aversa LS, Sibilla M, Mocellini F, Bioletto F, Ghigo E, Gasco V, Grottoli S. Evaluation of fluid status in patients with acromegaly through bioelectrical impedance vector analysis: a cross-sectional study. J Endocrinol Invest 2025; 48:1185-1195. [PMID: 39954196 PMCID: PMC12049396 DOI: 10.1007/s40618-025-02541-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/25/2024] [Accepted: 01/24/2025] [Indexed: 02/17/2025]
Abstract
PURPOSE The acromegalic state is associated with an increase in total body water and sodium. The aim of our study was to assess the hydration status of patients with acromegaly using bioimpedance vector analysis (BIVA), differentiating patients according to their disease status (active, medically controlled or cured) and to compare the confidence and tolerance ellipses of BIVA in those patients in relation to a reference healthy population. METHODS We analyzed data from 73 consecutive patients aged 18 years or older, diagnosed with acromegaly and undergoing regular follow-up at our Division for whom a BIVA analysis was available. Patients were evaluated through BIVA and insulin-like growth factor I (IGF-I), growth hormone (GH), serum sodium and potassium, creatinine, glucose, HbA1c and plasma and urine osmolality were collected. Exclusion criteria were concurrent presence of arginine-vasopressin deficiency, dysnatremia or the presence of pathologies known to significantly alter the extracellular fluid. RESULTS Sixty-nine patients (M/F 34/35, age 60 ± 14 years) were enrolled in the study. As expected, patients with active disease (n = 22) presented higher IGF-I and GH levels compared to other subjects. Patients with controlled disease (n = 33) were significantly older than other individuals (p = 0.028 vs. active disease, p = 0.024 vs. cured disease). Compared to a reference healthy population, patients with either active or medically controlled disease showed significant fluid overload (p < 0.0001 for both males and females) and BIVA confidence analysis demonstrated that there were no significant differences in hydration status between the two groups (p = 0.363). On the other hand, patients with cured disease (n = 14) showed reduced hydration status compared to patients with active disease (p = 0.016), although no difference was observed compared to patients with controlled disease (p = 0.308). CONCLUSION The results of our study demonstrate that patients with either active or medically controlled acromegaly present a significant overhydration compared to a healthy reference population and that alterations in body water content usually improve in individuals with cured disease.
Collapse
Affiliation(s)
- Emanuele Varaldo
- Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin, Turin, Italy
| | - Nunzia Prencipe
- Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin, Turin, Italy
| | - Alessandro Maria Berton
- Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin, Turin, Italy
| | - Daniela Cuboni
- Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin, Turin, Italy
| | - Luigi Simone Aversa
- Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin, Turin, Italy
| | - Michela Sibilla
- Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin, Turin, Italy
| | - Francesca Mocellini
- Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin, Turin, Italy
| | - Fabio Bioletto
- Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin, Turin, Italy
| | - Ezio Ghigo
- Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin, Turin, Italy
| | - Valentina Gasco
- Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin, Turin, Italy
| | - Silvia Grottoli
- Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin, Turin, Italy.
| |
Collapse
|
2
|
Morishita K, Nakamura K, Kubota T, Ota Y, Nabuchi M, Hibako K, Serizawa Y, Hoshi T. Recurrent Vomiting due to Severe Hyponatremic-Hypertensive Syndrome in an Elderly Patient. Intern Med 2025:4725-24. [PMID: 40090723 DOI: 10.2169/internalmedicine.4725-24] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/18/2025] Open
Abstract
Hyponatremic hypertensive syndrome (HHS) is a rare disorder, particularly in adults. A 76-year-old woman presented with vomiting and severe hyponatremia. The patient had been hospitalized four times over the past four years due to hyponatremia and recurrent vomiting. On admission, magnetic resonance angiography revealed left renal artery stenosis, which led to a diagnosis of HHS. Treatment with enalapril followed by tolvaptan improved the patient's condition, without the need for renal artery angioplasty. HHS should therefore be considered in patients with hyponatremia, hypertension, or recurrent vomiting. In addition to angiotensin-converting enzyme inhibitors and renal artery angioplasty, tolvaptan may also be a new effective treatment option for HHS.
Collapse
Affiliation(s)
- Koki Morishita
- Department of General Internal Medicine, Teine Keijinkai Hospital, Japan
| | - Kaito Nakamura
- Department of General Internal Medicine, Teine Keijinkai Hospital, Japan
| | - Takafumi Kubota
- Department of Neurology, Tohoku University Graduate School of Medicine, Japan
- Department of Epileptology, Tohoku University Hospital, Japan
| | - Yusuke Ota
- Department of General Internal Medicine, Teine Keijinkai Hospital, Japan
| | - Mirei Nabuchi
- Department of Cardiology, Teine Keijinkai Hospital, Japan
| | - Keita Hibako
- Department of General Internal Medicine, Teine Keijinkai Hospital, Japan
| | - Yoshimoto Serizawa
- Department of General Internal Medicine, Teine Keijinkai Hospital, Japan
| | - Tetsuya Hoshi
- Department of General Internal Medicine, Teine Keijinkai Hospital, Japan
| |
Collapse
|
3
|
Van Huele A, Everaert K, Gibson W, Wagg A, Abrams P, Wein A, Bower WF. LUTS in Older Adults: Definitions, Comorbidity Impact, Patient Priorities, and Treatment Strategies for Managing Daytime and/or Nighttime Symptoms - ICI-RS 2024. Neurourol Urodyn 2025; 44:592-600. [PMID: 39526631 DOI: 10.1002/nau.25624] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2024] [Accepted: 10/28/2024] [Indexed: 11/16/2024]
Abstract
INTRODUCTION Lower urinary tract symptoms (LUTS) are prevalent among older adults, a population that faces multiple medical challenges, with frailty being a major concern. Despite the high prevalence of LUTS, current treatment strategies for older adults are often inadequate. This paper aims to address these issues by defining daytime and/or nighttime LUTS and examining the impact of comorbid conditions on these symptoms. We will identify the priorities of older patients regarding LUTS management and propose treatment strategies to improve outcomes in this vulnerable population. METHODS This review is based on discussions at the ICI-RS 2024 meeting in Bristol, UK, alongside an extensive literature review examining LUTS in older adults. The review explores distinctions between daytime and nighttime symptoms, the impact of frailty, patient priorities, treatment strategies and the role of comorbidities. RESULTS LUTS in older adults present a complex and multifaceted challenge, with notable differences between daytime and nighttime manifestations, which may coexist. Clear definitions are needed. There is a lack of evidence that treating associated comorbidities will improve LUTS or urinary incontinence. Personalized care approaches, integrated into broader geriatric health strategies, are essential for addressing these symptoms. An ideal treatment strategy is proposed, focusing on daytime, nighttime or combined day- and nighttime LUTS. Further research is needed to refine treatment pathways and optimize outcomes for this population. CONCLUSIONS A comprehensive, individualized approach is necessary to address LUTS in older adults. Future research should focus on refining diagnostic definitions, exploring the interplay between comorbidities and LUTS, and developing patient-centered treatment strategies that account for both daytime and nighttime (or combined) symptoms.
Collapse
Affiliation(s)
| | - Karel Everaert
- Department of Urology, Ghent University Hospital, Ghent, Belgium
| | - William Gibson
- Division of Geriatric Medicine, University of Alberta, Edmonton, Alberta, Canada
| | - Adrian Wagg
- Division of Geriatric Medicine, University of Alberta, Edmonton, Alberta, Canada
| | - Paul Abrams
- Department of Urology, University of Bristol, Bristol, UK
| | - Alan Wein
- Desai-Seth Institute of Urology, University of Miami, Miami, Florida, USA
| | - Wendy F Bower
- Melbourne Medical School, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia
- Department of Physiotherapy, Royal Melbourne Hospital, Melbourne, Victoria, Australia
| |
Collapse
|
4
|
Pfeifer G, Cawkwell S. Interoceptive ageing and the impact on psychophysiological processes: A systematic review. Int J Psychophysiol 2025; 207:112483. [PMID: 39657288 DOI: 10.1016/j.ijpsycho.2024.112483] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2024] [Revised: 12/02/2024] [Accepted: 12/05/2024] [Indexed: 12/12/2024]
Abstract
Interoception, the perception and response to internal bodily states, significantly influences physical and mental wellbeing. While ageing is associated with interoceptive decline, research has primarily examined selective dimensions of interoception. Understanding these changes is vital as the global population ages, addressing age-related health issues and sustaining psychological wellbeing. This systematic review synthesised findings from 22 studies on age-related interoceptive changes and their impact on psychophysiological processes. Results showed age-related declines (48.4 %), no age differences (32.3 %), an age-related increase (16.13 %), and an inverted U-shaped curvilinear relationship (3.23 %) in interoceptive sensitivity across age groups and interoceptive dimensions. Three patterns emerged regarding psychophysiological processes in older adults: altered mind-body connections with age were associated with reduced high-arousal and increased positive emotional experiences, cognitive protective effects, and improved body representation that correlated with better interoceptive sensitivity. These patterns indicate the complex relationships between interoceptive ageing and psychophysiological processes, showing both, aspects of decline and compensatory mechanisms. We propose future research avenues to elucidate the functional significance of different interoceptive dimensions across the lifespan for optimised psychological wellbeing and health behaviours in older adults.
Collapse
Affiliation(s)
- Gaby Pfeifer
- School of Psychology, Faculty of Environmental and Life Sciences, University of Southampton, Southampton SO17 1BJ, United Kingdom.
| | - Sophie Cawkwell
- School of Humanities and Social Sciences, Leeds Beckett University, Leeds LS1 3HE, United Kingdom
| |
Collapse
|
5
|
Bioletto F, Berton AM, Barale M, Aversa LS, Sauro L, Presti M, Mocellini F, Sagone N, Ghigo E, Procopio M, Grottoli S. Skeletal fragility in pituitary disease: how can we predict fracture risk? Pituitary 2024; 27:789-801. [PMID: 39240510 PMCID: PMC11631825 DOI: 10.1007/s11102-024-01447-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 08/10/2024] [Indexed: 09/07/2024]
Abstract
Pituitary hormones play a crucial role in regulating skeletal physiology, and skeletal fragility is a frequent complication of pituitary diseases. The ability to predict the risk of fracture events is crucial for guiding therapeutic decisions; however, in patients with pituitary diseases, fracture risk estimation is particularly challenging. Compared to primary osteoporosis, the evaluation of bone mineral density by dual X-ray absorptiometry is much less informative about fracture risk. Moreover, the reliability of standard fracture risk calculators does not have strong validations in this setting. Morphometric vertebral assessment is currently the cornerstone in the assessment of skeletal fragility in patients with pituitary diseases, as prevalent fractures remain the strongest predictor of future fracture events. In recent years, new tools for evaluating bone quality have shown promising results in assessing bone impairment in patients with pituitary diseases, but most available data are cross-sectional, and evidence regarding the prediction of incident fractures is still scarce. Of note, apart from measures of bone density and bone quality, the estimation of fracture risk in the context of pituitary hyperfunction or hypofunction cannot ignore the evaluation of factors related to the underlying disease, such as its severity and duration, as well as the specific therapies implemented for its treatment. Aim of this review is to provide an up-to-date overview of all major evidence regarding fracture risk prediction in patients with pituitary disease, highlighting the need for a tailored approach that critically integrates all clinical, biochemical, and instrumental data according to the specificities of each disease.
Collapse
Affiliation(s)
- Fabio Bioletto
- Division of Endocrinology, Diabetes and Metabolism, Department of Medical Sciences, University of Turin, Corso Dogliotti 14, Turin, 10126, Italy.
| | - Alessandro Maria Berton
- Division of Endocrinology, Diabetes and Metabolism, Department of Medical Sciences, University of Turin, Corso Dogliotti 14, Turin, 10126, Italy
| | - Marco Barale
- Division of Oncological Endocrinology, Department of Medical Sciences, University of Turin, Turin, Italy
| | - Luigi Simone Aversa
- Division of Endocrinology, Diabetes and Metabolism, Department of Medical Sciences, University of Turin, Corso Dogliotti 14, Turin, 10126, Italy
| | - Lorenzo Sauro
- Division of Endocrinology, Diabetes and Metabolism, Department of Medical Sciences, University of Turin, Corso Dogliotti 14, Turin, 10126, Italy
| | - Michela Presti
- Division of Oncological Endocrinology, Department of Medical Sciences, University of Turin, Turin, Italy
| | - Francesca Mocellini
- Division of Endocrinology, Diabetes and Metabolism, Department of Medical Sciences, University of Turin, Corso Dogliotti 14, Turin, 10126, Italy
| | - Noemi Sagone
- Division of Endocrinology, Diabetes and Metabolism, Department of Medical Sciences, University of Turin, Corso Dogliotti 14, Turin, 10126, Italy
| | - Ezio Ghigo
- Division of Endocrinology, Diabetes and Metabolism, Department of Medical Sciences, University of Turin, Corso Dogliotti 14, Turin, 10126, Italy
| | - Massimo Procopio
- Division of Endocrinology, Diabetes and Metabolism, Department of Medical Sciences, University of Turin, Corso Dogliotti 14, Turin, 10126, Italy
| | - Silvia Grottoli
- Division of Endocrinology, Diabetes and Metabolism, Department of Medical Sciences, University of Turin, Corso Dogliotti 14, Turin, 10126, Italy
| |
Collapse
|
6
|
Kravchenko G, Stephenson SS, Gutowska A, Klimek K, Chrząstek Z, Pigłowska M, Kostka T, Sołtysik BK. The Concurrent Association of Magnesium and Calcium Deficiencies with Cognitive Function in Older Hospitalized Adults. Nutrients 2024; 16:3756. [PMID: 39519587 PMCID: PMC11547592 DOI: 10.3390/nu16213756] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2024] [Revised: 10/16/2024] [Accepted: 10/29/2024] [Indexed: 11/16/2024] Open
Abstract
Background/Objectives: Hypomagnesemia and hypocalcemia are common conditions among older adults that may contribute to cognitive decline. However, most of the existing research has focused primarily on dietary intake rather than the actual serum levels of these nutrients or examined them separately. This study aims to investigate the relationship between hypomagnesemia, hypocalcemia, and the concurrent presence of both deficiencies in relation to cognitive performance among seniors. Methods: A total of 1220 hospitalized patients aged 60 and older were included in the analysis. The participants were categorized into four groups: those with normal serum levels of magnesium and calcium, those with hypomagnesemia, those with hypocalcemia, and those with both serum magnesium and calcium deficiencies. To evaluate the potential influence of age, sex, common comorbidities, and disturbances in magnesium and calcium levels on cognitive performance, two general linear models were employed, using the Mini-Mental State Examination (MMSE) and Clock-Drawing Test (CDT) as dependent variables. Results: After adjusting for age, sex, body mass index, and comorbidities, the mean values for the MMSE and CDT were 23.33 (95%CI: 22.89-23.79) and 5.56 (95%CI: 5.29-5.83) for the group with normomagnesemia and normocalcemia, 22.59 (95%CI: 21.94-23.24) and 5.16 (95%CI: 4.77-5.54) for the group with hypomagnesemia, 19.53 (95%CI: 18.36-20.70) and 4.52 (95%CI: 3.83-5.21) for the group with hypocalcemia, and 21.14 (95%CI 19.99-22.29) and 4.28 (95%CI 3.61-4.95) for the group with both hypomagnesemia and hypocalcemia, respectively. Magnesium and calcium deficiencies contributed to MMSE and CDT variance in the general linear models. Conclusions: Our findings indicate that in addition to age, body mass index, and chronic heart failure, both hypomagnesemia and hypocalcemia are associated with reduced cognitive performance.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Bartłomiej K. Sołtysik
- Department of Geriatrics, Healthy Ageing Research Centre (HARC), Central Teaching Hospital of the Medical University of Lodz, Pomorska 251, 92-213 Łódź, Poland
| |
Collapse
|
7
|
Varaldo E, Sibilla M, Prencipe N, Berton AM, Cuboni D, Aversa LS, Mocellini F, Bioletto F, Ghigo E, Gasco V, Grottoli S. Desmopressin dose requirements in patients with permanent arginine vasopressin deficiency: a tertiary center experience. Pituitary 2024; 27:714-722. [PMID: 39266909 PMCID: PMC11513737 DOI: 10.1007/s11102-024-01454-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 08/24/2024] [Indexed: 09/14/2024]
Abstract
PURPOSE The desmopressin daily dose requirement is highly variable among patients with arginine vasopressin (AVP) deficiency (i.e. central diabetes insipidus) and few studies to date have evaluated this topic, with often inconclusive results. The aim of our study was to identify clinical and biochemical predictors of such dose requirements in a cohort of patients with a confirmed diagnosis of permanent AVP deficiency who have good and stable control under substitutive treatment. METHODS We retrospectively analyzed data of all patients with permanent AVP deficiency undergoing regular follow-up at our Division. Inclusion criteria were the presence of stable disease under therapy for at least 12 months and in good biochemical and clinical control. Patients with AVP deficiency who lacked intact thirst or had a disease duration of less than 12 months were excluded from the analysis. RESULTS Out of the 132 patients initially screened, 96 patients (M/F 44/52; age 51 [37-63] years) met the inclusion criteria. Patients on nasal spray therapy (n = 8) had a significantly longer disease duration (p = 0.002) than patients treated with oral lyophilizate (n = 88). In the bivariate analysis, considering only patients treated with the sublingual formulation, the drug dose was correlated positively with estimated glomerular filtration rate (eGFR) and weight (r = 0.410, p < 0.001; r = 0.224, p = 0.036, respectively) and negatively with age (r = - 0.433, p < 0.001). In the multivariate regression analysis taking into account age, weight, and eGFR, only age emerged as a significant predictor of the required sublingual desmopressin dose (β = - 1.426, p = 0.044). CONCLUSION Our data suggest that patient age appears to be the primary factor associated with the daily sublingual desmopressin dose required to achieve adequate clinical and biochemical control in patients with permanent AVP deficiency.
Collapse
Affiliation(s)
- Emanuele Varaldo
- Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin, Corso Dogliotti, 14, 10126, Turin, Italy.
| | - Michela Sibilla
- Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin, Corso Dogliotti, 14, 10126, Turin, Italy
| | - Nunzia Prencipe
- Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin, Corso Dogliotti, 14, 10126, Turin, Italy
| | - Alessandro Maria Berton
- Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin, Corso Dogliotti, 14, 10126, Turin, Italy
| | - Daniela Cuboni
- Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin, Corso Dogliotti, 14, 10126, Turin, Italy
| | - Luigi Simone Aversa
- Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin, Corso Dogliotti, 14, 10126, Turin, Italy
| | - Francesca Mocellini
- Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin, Corso Dogliotti, 14, 10126, Turin, Italy
| | - Fabio Bioletto
- Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin, Corso Dogliotti, 14, 10126, Turin, Italy
| | - Ezio Ghigo
- Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin, Corso Dogliotti, 14, 10126, Turin, Italy
| | - Valentina Gasco
- Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin, Corso Dogliotti, 14, 10126, Turin, Italy
| | - Silvia Grottoli
- Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin, Corso Dogliotti, 14, 10126, Turin, Italy
| |
Collapse
|
8
|
Imamura T, Izumida T, Narang N, Kinugawa K. A Lower Remote Dielectric Sensing Value Was Associated with Hypovolemia and Worse Clinical Outcomes. J Clin Med 2024; 13:3245. [PMID: 38892956 PMCID: PMC11172818 DOI: 10.3390/jcm13113245] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2024] [Revised: 05/21/2024] [Accepted: 05/30/2024] [Indexed: 06/21/2024] Open
Abstract
Background: Remote dielectric sensing (ReDS) systems can estimate the amount of lung fluid non-invasively and easily without expert techniques. The correlation between the elevated ReDS value and other modalities that estimate pulmonary congestion has been validated. The clinical implications of lower ReDS values, which may indicate hypovolemia, remain unknown. Methods: A total of 138 patients who were hospitalized for various cardiovascular-related problems and underwent ReDS value measurements at the index discharge in a blinded manner to the attending clinicians were eligible for inclusion. Patients with ReDS values > 30%, indicating the presence of pulmonary congestion, were excluded. The prognostic impact of lower ReDS values on all-cause readmission after index discharge was evaluated. Results: A total of 97 patients were included. The median age was 78 years, and 48 were men. The median ReDS value at index discharge was 26% (23%, 27%). A lower ReDS value correlated with smaller inferior vena cava maximum diameters (r = 0.46, p < 0.001) and higher blood urea nitrogen/creatinine ratios (r = -0.35, p < 0.001). A lower ReDS value (≤25%) was associated with a risk of all-cause readmissions with an unadjusted hazard ratio of 2.68 (95% confidence interval 1.09-6.59, p = 0.031) and an adjusted hazard ratio of 2.30 (95% confidence interval 0.92-5.78, p = 0.076). Its calculated cutoff of 25% significantly stratified the cumulative incidence of the primary outcome (36% versus 17%, p = 0.038). Conclusions: A lower ReDS value may indicate hypovolemia and be associated with the risk of all-cause readmission in patients hospitalized for cardiovascular diseases.
Collapse
Affiliation(s)
- Teruhiko Imamura
- Second Department of Internal Medicine, University of Toyama, Toyama 930-0194, Japan
| | - Toshihide Izumida
- Second Department of Internal Medicine, University of Toyama, Toyama 930-0194, Japan
| | - Nikhil Narang
- Advocate Christ Medical Center, Oak Lawn, IL 60453, USA
| | - Koichiro Kinugawa
- Second Department of Internal Medicine, University of Toyama, Toyama 930-0194, Japan
| |
Collapse
|
9
|
Soleilhavoup S, Essig M, Levassort H. [Hydrosodium balance in aging]. SOINS. GERONTOLOGIE 2024; 29:21-30. [PMID: 38331521 DOI: 10.1016/j.sger.2023.12.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/10/2024]
Abstract
One of the kidney's major functions is to adjust the water and sodium balance in order to maintain a state of equilibrium. In the course of aging, even in the absence of renal pathology, changes are observed not only in renal macrostructure (reduction in kidney size, increase in the number of cysts), but also in microstructure (arteriosclerosis, glomerulosclerosis, fibrosis and tubular atrophy). All these changes can disrupt the homeostasis of water and sodium balances. The aim of this article is to review the physiology of water and sodium stores, and to assess the impact of aging on the regulatory loops of these different systems.
Collapse
Affiliation(s)
- Sébastien Soleilhavoup
- Service de néphrologie, Université Paris-Saclay, Site Ambroise-Paré, AP-HP, 9 avenue Charles-de-Gaulle, 92100 Boulogne-Billancourt, France
| | - Marie Essig
- Service de néphrologie, Université Paris-Saclay, Site Ambroise-Paré, AP-HP, 9 avenue Charles-de-Gaulle, 92100 Boulogne-Billancourt, France; Inserm UMRS 1018, Équipe épidémiologie clinique, Université Paris-Saclay, UVSQ, CESP, Villejuif, France
| | - Hélène Levassort
- Service de néphrologie, Université Paris-Saclay, Site Ambroise-Paré, AP-HP, 9 avenue Charles-de-Gaulle, 92100 Boulogne-Billancourt, France; Inserm UMRS 1018, Équipe épidémiologie clinique, Université Paris-Saclay, UVSQ, CESP, Villejuif, France; Service de gériatrie, Université Paris-Saclay, Site Ambroise-Paré, AP-HP, 9 avenue Charles-de-Gaulle, 92100 Boulogne-Billancourt, France.
| |
Collapse
|
10
|
Fujishima R, Ushimaru S, Sumi H, Aso M, Akaike T, Shiizaki K, Tominaga N. Effect of denosumab on bone mineral density in a postmenopausal osteoporotic woman with prolonged chronic mild hyponatremia. Osteoporos Int 2023; 34:2139-2140. [PMID: 37723308 DOI: 10.1007/s00198-023-06898-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/17/2023] [Accepted: 08/23/2023] [Indexed: 09/20/2023]
Affiliation(s)
- Rie Fujishima
- Division of Nephrology and Hypertension, Kawasaki Municipal Tama Hospital, 1-30-37, Syukugawara, Tama-Ku, Kawasaki, Kanagawa, 214-8525, Japan
- Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, 2-16-1, Sugao, Miyamae-Ku, Kawasaki, Kanagawa, 216-8511, Japan
| | - Shu Ushimaru
- Division of Nephrology and Hypertension, Kawasaki Municipal Tama Hospital, 1-30-37, Syukugawara, Tama-Ku, Kawasaki, Kanagawa, 214-8525, Japan
- Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, 2-16-1, Sugao, Miyamae-Ku, Kawasaki, Kanagawa, 216-8511, Japan
| | - Hirofumi Sumi
- Division of Nephrology and Hypertension, Kawasaki Municipal Tama Hospital, 1-30-37, Syukugawara, Tama-Ku, Kawasaki, Kanagawa, 214-8525, Japan
- Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, 2-16-1, Sugao, Miyamae-Ku, Kawasaki, Kanagawa, 216-8511, Japan
| | - Mea Aso
- Division of Nephrology and Hypertension, Kawasaki Municipal Tama Hospital, 1-30-37, Syukugawara, Tama-Ku, Kawasaki, Kanagawa, 214-8525, Japan
- Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, 2-16-1, Sugao, Miyamae-Ku, Kawasaki, Kanagawa, 216-8511, Japan
| | - Takashi Akaike
- Division of Nephrology and Hypertension, Kawasaki Municipal Tama Hospital, 1-30-37, Syukugawara, Tama-Ku, Kawasaki, Kanagawa, 214-8525, Japan
| | - Kazuhiro Shiizaki
- Nephrology and Dialysis Clinic Koga, 187, Nishiushigaya, Koga, Ibaraki, 306-0233, Japan
| | - Naoto Tominaga
- Division of Nephrology and Hypertension, Kawasaki Municipal Tama Hospital, 1-30-37, Syukugawara, Tama-Ku, Kawasaki, Kanagawa, 214-8525, Japan.
- Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, 2-16-1, Sugao, Miyamae-Ku, Kawasaki, Kanagawa, 216-8511, Japan.
- Division of Nephrology and Hypertension, Kawasaki Municipal Tama Hospital, Kawasaki, Kanagawa, 214-8525, Japan.
| |
Collapse
|
11
|
Elsamad G, Mecawi AS, Pauža AG, Gillard B, Paterson A, Duque VJ, Šarenac O, Žigon NJ, Greenwood M, Greenwood MP, Murphy D. Ageing restructures the transcriptome of the hypothalamic supraoptic nucleus and alters the response to dehydration. NPJ AGING 2023; 9:12. [PMID: 37264028 PMCID: PMC10234251 DOI: 10.1038/s41514-023-00108-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/16/2023] [Accepted: 05/04/2023] [Indexed: 06/03/2023]
Abstract
Ageing is associated with altered neuroendocrine function. In the context of the hypothalamic supraoptic nucleus, which makes the antidiuretic hormone vasopressin, ageing alters acute responses to hyperosmotic cues, rendering the elderly more susceptible to dehydration. Chronically, vasopressin has been associated with numerous diseases of old age, including type 2 diabetes and metabolic syndrome. Bulk RNAseq transcriptome analysis has been used to catalogue the polyadenylated supraoptic nucleus transcriptomes of adult (3 months) and aged (18 months) rats in basal euhydrated and stimulated dehydrated conditions. Gene ontology and Weighted Correlation Network Analysis revealed that ageing is associated with alterations in the expression of extracellular matrix genes. Interestingly, whilst the transcriptomic response to dehydration is overall blunted in aged animals compared to adults, there is a specific enrichment of differentially expressed genes related to neurodegenerative processes in the aged cohort, suggesting that dehydration itself may provoke degenerative consequences in aged rats.
Collapse
Affiliation(s)
- Ghadir Elsamad
- Molecular Neuroendocrinology Research Group, Bristol Medical School: Translational Health Sciences, Dorothy Hodgkin Building, University of Bristol, Bristol, England
| | - André Souza Mecawi
- Laboratory of Molecular Neuroendocrinology, Department of Biophysics, Paulista School of Medicine, Federal University of São Paulo, São Paulo, Brazil
| | - Audrys G Pauža
- Molecular Neuroendocrinology Research Group, Bristol Medical School: Translational Health Sciences, Dorothy Hodgkin Building, University of Bristol, Bristol, England
- Translational Cardio-Respiratory Research Group, Department of Physiology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
| | - Benjamin Gillard
- Molecular Neuroendocrinology Research Group, Bristol Medical School: Translational Health Sciences, Dorothy Hodgkin Building, University of Bristol, Bristol, England
| | - Alex Paterson
- Molecular Neuroendocrinology Research Group, Bristol Medical School: Translational Health Sciences, Dorothy Hodgkin Building, University of Bristol, Bristol, England
- Insilico Consulting Ltd., Wapping Wharf, Bristol, England
| | - Victor J Duque
- Laboratory of Molecular Neuroendocrinology, Department of Biophysics, Paulista School of Medicine, Federal University of São Paulo, São Paulo, Brazil
| | - Olivera Šarenac
- Institute of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
- Department of Safety Pharmacology, Abbvie, North Chicago, Illinois, USA
| | - Nina Japundžić Žigon
- Institute of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
| | - Mingkwan Greenwood
- Molecular Neuroendocrinology Research Group, Bristol Medical School: Translational Health Sciences, Dorothy Hodgkin Building, University of Bristol, Bristol, England
| | - Michael P Greenwood
- Molecular Neuroendocrinology Research Group, Bristol Medical School: Translational Health Sciences, Dorothy Hodgkin Building, University of Bristol, Bristol, England
| | - David Murphy
- Molecular Neuroendocrinology Research Group, Bristol Medical School: Translational Health Sciences, Dorothy Hodgkin Building, University of Bristol, Bristol, England.
| |
Collapse
|